A real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System

References

• Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–1309. doi: 10.1126/science.2479986
   PubMed Web of Science ®Google Scholar
• Tischer E, Gospodarowicz D, Mitchell R, et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun. 1989;165(3):1198–1206. doi: 10.1016/0006-291X(89)92729-0
   PubMed Web of Science ®Google Scholar
• Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264. doi: 10.1016/j.cell.2019.01.021
   PubMed Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmol. 2015;122(1):146–152. doi: 10.1016/j.ophtha.2014.07.041
   PubMed Web of Science ®Google Scholar
• Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019;9(5):e22031. doi: 10.1136/bmjopen-2018-022031
   PubMed Web of Science ®Google Scholar
• Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020;15(2):199–210. doi: 10.1007/s11739-019-02253-7
   PubMed Web of Science ®Google Scholar
• Hanna RM, Barsoum M, Arman F, et al. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572–580. doi: 10.1016/j.kint.2019.02.042
   PubMed Web of Science ®Google Scholar
• Maloney MH, Payne SR, Herrin J, et al. Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmol. 2021;128(3):417–424. doi: 10.1016/j.ophtha.2020.07.062
   PubMed Web of Science ®Google Scholar
• Zehden JA, Mortensen XM, Reddy A, et al. Systemic and ocular adverse events with intravitreal anti-VEGF therapy used in the treatment of diabetic retinopathy: a review. Curr Diab Rep. 2022;22(10):525–536. doi: 10.1007/s11892-022-01491-y
   PubMed Web of Science ®Google Scholar
• Maloney MH, Schilz SR, Herrin J, et al. Risk of systemic adverse events associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmol. 2019;126(7):1007–1015. doi: 10.1016/j.ophtha.2018.09.040
   PubMed Web of Science ®Google Scholar
• Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018;10(10):D7419. doi: 10.1002/14651858.CD007419.pub6
   Google Scholar
• Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3(3):D5139. doi: 10.1002/14651858.CD005139.pub4
   Google Scholar
• Jhaveri CD, Glassman AR, Ferris FR, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med. 2022;387(8):692–703. doi: 10.1056/NEJMoa2204225
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmol. 2016;123(6):1351–1359. doi: 10.1016/j.ophtha.2016.02.022
   PubMed Web of Science ®Google Scholar
• Ngo Ntjam N, Thulliez M, Paintaud G, et al. Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials. JAMA Ophthalmol. 2021;139(6):1–11. doi: 10.1001/jamaophthalmol.2021.0640
   PubMed Web of Science ®Google Scholar
• Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014;132(11):1317–1326. doi: 10.1001/jamaophthalmol.2014.2333
   PubMed Web of Science ®Google Scholar
• Plyukhova AA, Budzinskaya MV, Starostin KM, et al. Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies. J Clin Med. 2020;9(5):1522. doi: 10.3390/jcm9051522
   PubMed Web of Science ®Google Scholar
• Ma P, Pan X, Liu R, et al. Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2022;13:1017889. doi: 10.3389/fphar.2022.1017889
   PubMed Web of Science ®Google Scholar
• Fukazawa C, Hinomura Y, Kaneko M, et al. Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf. 2018;27(12):1402–1408. doi: 10.1002/pds.4672
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Khaleel MA, Khan AH, Ghadzi S, et al. A standardized dataset of a spontaneous adverse event reporting system. Healthcare. 2022;10(3):420. doi: 10.3390/healthcare10030420
   Web of Science ®Google Scholar
• Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436. doi: 10.1002/pds.1742
   PubMed Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486. doi: 10.1002/pds.677
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• EYLEA® (aflibercept) injection. FDA. [ Updated 2023 Feb 8; cited 2023 Jul 5]. Updated 2023 Feb 8: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s075lbl.pdf
   Google Scholar
• AVASTIN® (bevacizumab) injection. FDA. [ Updated 2022 Sep 18; cited 2023 Jul 5]. Updated 2022 Sep 18: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf
   Google Scholar
• BEOVU® (brolucizumab-dbll) injection. FDA. [ Updated 2022 Dec 19; cited 2023 Jul 5]. Updated 2022 Dec 19: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s017lbl.pdf
   Google Scholar
• MACUGEN® (pegaptanib) injection. FDA. [ Updated 2011 Oct 12; cited 2023 Jul 5]. Updated 2011 Oct 12: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf
   Google Scholar
• LUCENTIS® (ranibizumab) injection. FDA. [ Updated 2018 Mar 20; cited 2023 Jul 5]. Updated 2018 Mar 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf
   Google Scholar
• Zhu Y, Zhang T, Xu G, et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev. 2016;12(12):D11160. doi: 10.1002/14651858.CD011160.pub2
   Google Scholar
• Storey PP, Patel D, Garg S. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can J Ophthalmol. 2020;55(4):286–292. doi: 10.1016/j.jcjo.2020.01.015
   PubMed Web of Science ®Google Scholar
• Singh R, Davoudi S, Ness S. Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2399–2416. doi: 10.1007/s00417-022-05607-8
   PubMed Web of Science ®Google Scholar
• Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmol. 2018;125(1):66–74. doi: 10.1016/j.ophtha.2017.07.005
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Flynn HJ, Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–208. doi: 10.1016/j.ajo.2011.11.035
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Flynn HJ, Miller D, et al. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmol. 2013;120(7):1448–1453. doi: 10.1016/j.ophtha.2012.12.009
   PubMed Web of Science ®Google Scholar
• Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694–696. doi: 10.4103/0301-4738.99855
   PubMed Web of Science ®Google Scholar
• Xu K, Mousa R, Loewenstein A, et al. Management and visual outcomes of acute bacterial endophthalmitis following intravitreal injection of contaminated bevacizumab in a single day. Ophthalmic Surg Lasers Imaging Retina. 2020;51(6):346–352. doi: 10.3928/23258160-20200603-05
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Rosenfeld PJ, Stewart MW, et al. Avastin doesn’t blind people, people blind people. Am J Ophthalmol. 2012;153(2):196–203. doi: 10.1016/j.ajo.2011.11.023
   PubMed Web of Science ®Google Scholar
• Sen S, Mishra C, Kannan NB, et al. Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections: a multicentric study. Semin Ophthalmol. 2021;36(5–6):413–422. doi: 10.1080/08820538.2021.1896746
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787–794. doi: 10.1038/eye.2013.107
   PubMed Web of Science ®Google Scholar
• Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021;105(3):473–491. doi: 10.1016/j.mcna.2021.01.003
   PubMed Web of Science ®Google Scholar
• Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19(3):227–234. doi: 10.1111/1469-0691.12118
   PubMed Web of Science ®Google Scholar
• Ersoz MG, Karacorlu M, Arf S, et al. Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management. Surv Ophthalmol. 2017;62(4):493–505. doi: 10.1016/j.survophthal.2017.03.004
   PubMed Web of Science ®Google Scholar
• Ueta T, Noda Y, Toyama T, et al. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. Ophthalmol. 2014;121(11):2193–2203. doi: 10.1016/j.ophtha.2014.05.022
   PubMed Web of Science ®Google Scholar
• Jiang L, Peng L, Zhou Y, et al. Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study. Front Med. 2023;10:1100397. doi: 10.3389/fmed.2023.1100397
   Web of Science ®Google Scholar
• Lee WA, Shao SC, Liao TC, et al. Comparative risk of arterial thromboembolic events between aflibercept and ranibizumab in patients with maculopathy: a population-based retrospective cohort study. BioDrugs. 2021;35(5):579–588. doi: 10.1007/s40259-021-00497-4
   PubMed Web of Science ®Google Scholar
• Dhodapkar MM, Shi X, Ramachandran R, et al. Characterization and corroboration of safety signals identified from the US food and drug Administration adverse event reporting system, 2008-19: cross sectional study. BMJ. 2022;379:e71752. doi: 10.1136/bmj-2022-071752
   Google Scholar
• Huang S, Guo Z, Wang M, et al. Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert Opin Drug Saf. 2023;22(2):175–181. doi: 10.1080/14740338.2023.2189235
   PubMed Web of Science ®Google Scholar